The transaction is sourced from an SEC EDGAR Form 8-K filing published on February 5, 2025. Based on the facts provided, the deal's status is pending regulatory approval.
On the financial advisory side, William Blair served as buyside financial adviser to GHO and Ampersand, the acquiring parties, and Alvarez & Marsal also served as financial advisor to GHO and Ampersand. In addition to these two financial advisors, the source sentence notes that ClearView Healthcare Partners served as commercial advisor to GHO and Ampersand, rounding out a multi-advisor team on the buy side. No financial advisor to Avid Bioservices, the target, is identified in the facts provided.
On the legal side, Ropes & Gray served as legal counsel to GHO and Ampersand, the acquiring side of the transaction. No legal advisor to Avid Bioservices is identified in the available material.
Beyond confirming that this is a cash acquisition structured as a take-private with a disclosed value of 1,100,000,000 dollars, no further detail on the specific per-share price or other terms of the cash consideration is included in the facts available.
A number of elements of this deal are not disclosed. No financial or legal advisor to Avid Bioservices, the target, is identified, and no expected closing date is given. The facts also do not specify the per-share purchase price or the regulatory approvals required to complete the transaction.